www.klinickafarmakologie.cz / Klin Farmakol Farm. 2026;40(3):158-163 / KLINICKÁ FARMAKOLOGIE A FARMACIE 163 HLAVNÍ TÉMA Aktuální možnosti inzulinoterapie 6. Simoni RD, Hill RL, Vaughan M. The discovery of insulin: the work of Frederick Banting and Charles Best. J Biol Chem. 2002;277(26):e1-e2. 7. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008;3(1):90-97. 8. Zaykov AN, Mayer JP, DiMarchi RD. Pursuit of a perfect insulin. Nat Rev Drug Discov. 2016;15(6):425-439. 9. Kang S, Brange J, Burch A, et al. Subcutaneous insulin absorption explained by insulin’s physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care. 1991;14(11):942-948. 10. Cheng R, Taleb N, Stainforth-Dubois M, et al. The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab. 2021;320(5):E886-E890. 11. Howey DC. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402. 12. Hirsch IB, Juneja R, Beals JM, et al. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(5):733-755. 13. Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17(7):682-688. 14. Andersen G, Meiffren G, Lamers D, et al. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab. 2018;20(11):2627-2632. 15. Hagedorn HC, Jensen BN, Krarup NB, et al. Protamine insulinate. JAMA. 1936;106(3):177-180. 16. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003;26(5):1490-1496. 17. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228): 443-445. 18. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498-1504. 19. Becker RHA, Dahmen R, Bergmann K, et al. New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care. 2015;38(4):637-643. 20. Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6(2):e009421. 21. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong- -acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191-204. 22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat- -to-target non-inferiority trial. Lancet. 2012;379(9825):1489-1497. 23. Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. Endocr Rev. 2024;45(3):379-413. 24. Oleck J, Kassam S, Goldman JD. Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr. 2016;29(3):180-184. 25. Bakh NA, Bisker G, Lee MA, et al. Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling. Adv Healthc Mater. 2017;6(22):1700601. 26. Subramanian S, Khan F, Hirsch IB. New advances in type 1 diabetes. BMJ. 2024;384. 27. Teo E, Hassan N, Tam W, et al. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022;65(4):604-619. 28. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes – 2026. Diabetes Care. 2026;49(Suppl 1):S150. 29. Ware J, Hovorka R. Recent advances in closed-loop insulin delivery. Metabolism. 2022;127:154953. 30. Klonoff DC, Kerr D. Smart pens will improve insulin therapy. J Diabetes Sci Technol. 2018;12(3):551-553. 31. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes – 2026. Diabetes Care. 2026;49(Suppl 1):S132-S149. 32. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5): 1520-1574. 33. Kudva YC, Henderson RJ, Kanapka LG, et al. Automated insulin delivery in older adults with type 1 diabetes. NEJM Evid. 2025;4(1):EVIDoa2400200. ODBORNÝ GARANT: MUDr. Pavel Rutar Interní oddělení, FN Motol a Homolka v Praze POŘADATEL: SOLEN, s. r. o., ve spolupráci s Interním oddělením, FN Motol a Homolka v Praze POČET KREDITŮ 2 Registrace ZDARMA TERMÍN březen 2026 až únor 2027 dostupný na online.solen.cz ON LINE KURZ OBSAH KURZU Současný pohled na využití NSA a kombinaci analgetik v léčbě muskuloskeletální bolesti – MUDr. Marek Hakl, Ph.D. Fixní kombinace naproxenu a esomeprazolu – novinka v léčbě bolesti u revmatických onemocnění – MUDr. Marta Olejárová, CSc. Místo naproxenu mezi ostatními nesteroidními antirevmatiky používanými v léčbě bolesti a zánětu u nejčastějších revmatických chorob – prof. MUDr. Pavel Horák, CSc. Léčba chronické bolesti – MUDr. Marek Hakl, Ph.D. Současný pohled na využití NSA v muskuloskeletální bolesti: role kombinace naproxen-esomeprazol PARTNER
RkJQdWJsaXNoZXIy NDA4Mjc=